drugset / Trial / NCT00265005

Safety and Efficacy of Tissue Plasminogen Activator (tPA) in Neonates and Infants

NCT00265005

Phase 1 Terminated 12 enrolled University of Louisville Genentech, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if alteplase is effective in dissolving a clot in a catheter in a large vein (central venous line or PICC line) or artery in infants less than 6 months of age.

Timeline

Start
2005-06
Primary completion
2009-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 1 mg/ml Intravenous
Subject Alteplase Protein / enzyme biologic 2 mg/ml Intravenous

Indications